EGFR and gastric adenocarcinoma: In a clinical setting, when erlotinib, an oral EGFR inhibitor, was administered to metastatic or unresectable cases of gastro-esophageal (GE) junction and gastric adenocarcinomas in SWOG0127 trials 31, more cases of GE junction cancer than of gastric cancer responded clinically.